Drug therapy for attention-deficit/hyperactivity disorder-like symptoms in autistic disorder

Journal of Paediatrics and Child Health

Volumn 43, Issue 1-2, 2007, Pages 19-24

  Hazell, Philip ^a,b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b Hospital Rd   (Australia)

Author keywords

Adverse effect; Attention deficit disorder with hyperactivity; Autistic disorder; Drug therapy; Treatment efficacy

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLOMIPRAMINE; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; DONEPEZIL; FLUOXETINE; GUANFACINE; HALOPERIDOL; LAMOTRIGINE; METHYLPHENIDATE; MIRTAZAPINE; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; VALPROIC ACID;

ABSENCE OF SIDE EFFECTS; AGGRESSIVENESS; AGITATION; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR DISORDER; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DECREASED APPETITE; DISEASE EXACERBATION; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; FATIGUE; HUMAN; HYPERACTIVITY; HYPERSALIVATION; INCREASED APPETITE; INDIVIDUALIZATION; IRRITABILITY; MENTAL INSTABILITY; NAUSEA; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SUSTAINED DRUG RELEASE; TINNITUS; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUTISTIC DISORDER; CHILD; HUMANS;

EID: 33845749041     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2007.00995.x     Document Type: Review

References (24)

1. Research Units on Pediatric Psychopharmacology Autistic Disorder Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch. Gen. Psychiatry 2005; 62: 1266-74.
2. Tsai S. Children with autistic disorder spectrum disorder: medicine today and in the new millenium. Focus on Autistic Disorder and Other Developmental Disabilities 2000; 15: 138-45.
3. Aman MG, Lam KS, Van Bourgondein ME. Medication patterns in patients with autistic disorder: temporal, regional, and demographic influences. J. Child Adolesc. Psychopharmacol. 2005; 15: 116-26.
4. Stigler KA, Desmond LA, Posey DJ, Wiegand RE, McDougle CJ. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J. Child Adolesc. Psychopharmacol. 2004; 14: 49-56.
5. Quintana H, Birmaher B, Stedge D et al. Use of methylphenidate in the treatment of children with autistic disorder. J. Autism Dev. Disord. 1995; 25: 283-94.
6. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autistic disorder and symptoms of attention-deficit hyperactivity disorder. J. Autism Dev. Disord. 2000; 30: 245-55.
7. Jaselskis CA, Cook EH Jr, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J. Clin. Psychopharmacol. 1992; 12: 322-7.
8. Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi SD. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autistic disorder. J. Clin. Psychiatry 1992; 53: 77-82.
9. Posey DJ, Puntney JI, Sasher TM, Kem DL, McDougle CJ. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J. Child Adolesc. Psychopharmacol. 2004; 14: 233-41.
10. Barnard L, Young AH, Pearson J, Geddes J, O'Brien G. A systematic review of the use of atypical antipsychotics in autistic disorder. J. Psychopharmacol. 2002; 16: 93-101.
11. Remington G, Sloman L, Konstantareas M, Parker K, Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J. Clin. Psychopharmacol. 2001; 21: 440-4.
12. Research Units on Pediatric Psychopharmacology Autistic Disorder Network. Risperidone in children with autistic disorder and serious behavioral problems. N. Engl. J. Med. 2002; 347: 314-21.
13. Findling RL, McNamara NK, Gracious BL et al. Quetiapine in nine youths with autistic disorder. J. Child Adolesc. Psychopharmacol. 2004; 14: 287-94.
14. Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J. Child Adolesc. Psychopharmacol. 2004; 14: 455-63.
15. Jou R, Handen B, Hardan A. Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J. Child Adolesc. Psychopharmacol. 2005; 15: 325-30.
16. Fatemi SH, Realmuto GM, Khan L, Thuras P. Fluoxetine in treatment of adolescent patients with autistic disorder: a longitudinal open trial. J. Autism Dev. Disord. 1998; 28: 303-7.
17. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch. Gen. Psychiatry 1993; 50: 441-7.
18. Brasic JR, Barnett JY, Sheitman BB, Tsaltas MO. Adverse effects of clomipramine. J. Am. Acad. Child Adolesc. Psychiatry 1997; 36: 1165-6.
19. Posey DJ, Guenin KD, Kohn AE, Swiezy NB, McDougle CJ. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J. Child Adolesc. Psychopharmacol. 2001; 11: 267-77.
20. Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S. An open trial of divalproex sodium in autistic disorder spectrum disorders. J. Clin. Psychiatry 2001; 62: 530-4.
21. Hardan AY, Jou RJ, Handen BL. A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders. J. Child Adolesc. Psychopharmacol. 2004; 14: 426-32.
22. Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmerman AW. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J. Autism Dev. Disord. 2001; 31: 175-81.
23. Hardan AY, Handen BL. A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J. Child Adolesc. Psychopharmacol. 2002; 12: 237-41.
24. Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J. Am. Acad. Child Adolesc. Psychiatry 2003; 42: 886-94.